Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ADoTope-MC003
- Development stage
- Preclinical
- Lead developer
- Medicovestor
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
ADoTope-MC003 is a preclinical **folate receptor alpha-targeted dual-payload bi-epitope antibody-drug conjugate** being developed for platinum-resistant epithelial ovarian cancer. The asset is built on the ADoTope platform and comprises two fully human high-affinity IgG1 antibodies, Clone 65 and Clone 91, that bind distinct non-overlapping epitopes on folate receptor alpha, functionally increasing target engagement on FRα-expressing tumor cells. In reported preclinical studies, Clone 65 was conjugated to gemcitabine and Clone 91 to exatecan through enzyme-sensitive linkers, creating a fixed-combination chemoimmunotherapy-style ADC designed to deliver mechanistically distinct payloads while also retaining antibody-mediated effector activity such as ADCC. Public conference abstracts describe enhanced in vitro potency versus corresponding single-payload comparators and activity in platinum-resistant ovarian cancer models, supporting further development in FRα-positive ovarian cancer.
- Brand names
- ADoTope
- Other names
- ADoTope FRα ADC
02
Targets
DNATOP1 (DNA Topoisomerase I)FOLR1 (FRα)
Beyond the preview
Go deeper on ADoTope-MC003.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ADoTope-MC003.